Novartis AG had reason to cheer in May when an appeals court upheld the validity of two patents covering its Exelon Patch (rivastigmine) for Alzheimer’s disease. But the victory was short-lived. Four months later, a panel of administrative judges at the US Patent and Trademark Office concluded several of the patent claims were unpatentable.
The conflicting opinions highlight the challenges innovators face from the PTO’s new inter partes review (IPR) proceeding. The process was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?